<DOC>
	<DOCNO>NCT01794234</DOCNO>
	<brief_summary>This observational study evaluate efficacy safety Pegasys ( peginterferon alfa-2a ) patient chronic hepatitis B fail antiviral treatment nucleoside ( nucleotide ) analogue . Data collect patient treat accord current Summary Product Characteristics local standard care regulation 48 week treatment 24 week follow-up .</brief_summary>
	<brief_title>An Observational Study Pegasys ( Peginterferon Alfa-2a ) Patients With Chronic Hepatitis B Who Have Failed Antiviral Treatment With Nucleoside ( Nucleotide ) Analogues</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Positive HBsAg 6 month assignment treatment Pegasys Detectable HBV DNA ( measure PCR ) HBeAg positive negative patient Patients previously treat nucleoside ( nucleotide ) analogue fail antiviral treatment assign treatment Pegasys accord local therapeutic standard Elevated serum alanine aminotransferase ( ALT ) Chronic hepatitis B confirm liver biopsy noninvasive assessment ( FibroScan ) , ARFI , FibroTest ) clinical evaluation Contraindications treatment Pegasys accord Summary Product Characteristics Hepatocellular carcinoma and/or severe hepatic dysfunction decompensated cirrhosis liver Immunosuppression , immunomodulatory chemotherapy within last 6 month prior start Pegasys treatment Planned Pegasys antiviral treatment Pegasys therapy Chronic liver disease chronic hepatitis B Pregnant breastfeed woman Inadequate hematologic function Autoimmunology disorder Coinfection chronic hepatitis C HIV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>